PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Antipsychotics for ICU Delirium: No Gain in Delirium- or Coma-Free Days

haloperidolquetiapineziprasidoneantipsychoticsdeliriumcritical careICUmeta-analysissystematic reviewtrial sequential analysismortalitymechanical ventilation Critical Care / ICU

Background Information

Antipsychotics show limited efficacy in treating ICU delirium.

Delirium in critically ill patients can lead to worse outcomes, and understanding effective treatments is crucial for improving patient care. The meta-analysis found no significant benefit of antipsychotics in reducing delirium duration or mortality in ICU patients. With limited efficacy shown for antipsychotics, alternative strategies for delirium management in the ICU may be needed. Further research is warranted. Antipsychotics do not significantly improve delirium outcomes in ICU patients.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Carayannopoulos KL, Alshamsi F, Chaudhuri D, Spatafora L, Piticaru J, Campbell K, Alhazzani W, Lewis K

Citation: Carayannopoulos KL, Alshamsi F, Chaudhuri D, et al. Antipsychotics in the Treatment of Delirium in Critically Ill Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Critical care medicine. 2024;52(7):1087-1096. doi:10.1097/CCM.0000000000006251

Article Links: PubMed · Journal / DOI

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.